Opt-IVF Improves Outcomes in Poor Responders by Enhancing Clinical Pregnancy Rates

The superovulation phase heavily influences the success and cost-effectiveness of assisted reproductive technology (ART). Previous studies have shown that using the clinical decision support tool Opt-IVF for hormone dosing can increase the number of high-quality embryos, reduce hormone dosages, and minimize the need for ultrasound testing. 

The aim of a new study was to assess whether Opt-IVF improves clinical pregnancy rates in routine practice. 

In this retrospective, single-center cohort study spanning 24 months, 204 women aged 25-45 underwent superovulation with hormone doses recommended by Opt-IVF (intervention group). In contrast, 207 women were treated without Opt-IVF guidance (control group).

It was observed that the Opt-IVF group required significantly lower cumulative gonadotropin doses than the control group. Additionally, the Opt-IVF group produced 20% more total embryos and 50% more high-quality embryos. Although overall clinical pregnancy rates, including canceled cycles, were higher in the control group (35% vs. 45%), the Opt-IVF group showed significantly higher pregnancy rates among older patients and poor responders.

The results demonstrated that Opt-IVF significantly improved outcomes for older patients and poor responders, making it a valuable tool in reproductive medicine. By reducing hormone doses and eliminating the need for post-day-five ultrasound testing, Opt-IVF enhances the number of embryos and pregnancy rates, offering infertility specialists an effective means of providing personalized care and increasing the chances of successful pregnancies in IVF treatments.

Source: Diwekar U, Joag S, Patel N, et al. Indian Obstetrics and Gynaecology. 2024 Jul 23;14(2).